Oculis Holding Ag Ordinary Shares

Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema

Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis

Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting

Oculis to Participate in Upcoming Investor Conferences

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update